Results 51 to 60 of about 8,194 (217)

Contributions of Animal Models to the Mechanisms and Therapies of Transthyretin Amyloidosis

Frontiers in Physiology, 2019
Transthyretin amyloidosis (ATTR amyloidosis) is a fatal systemic disease caused by amyloid deposits of misfolded transthyretin, leading to familial amyloid polyneuropathy and/or cardiomyopathy, or a rare oculoleptomeningeal amyloidosis.
Ridwan Babatunde Ibrahim, Ridwan Babatunde Ibrahim, Yo-Tsen Liu, Yo-Tsen Liu, Yo-Tsen Liu, Yo-Tsen Liu, Ssu-Yu Yeh, Jin-Wu Tsai, Jin-Wu Tsai   +8 more
doaj   +1 more source

Tissue Characterization in Cardiac Amyloidosis

Biomedicines, 2022
Cardiac amyloidosis (CA) has long been considered a rare disease, but recent advancements in diagnostic tools have led to a reconsideration of the epidemiology of CA. Amyloid light-chain (AL) and transthyretin (ATTR) amyloidoses are the most common forms
Veronica Musetti, Francesco Greco, Vincenzo Castiglione, Alberto Aimo, Cataldo Palmieri, Dario Genovesi, Assuero Giorgetti, Michele Emdin, Giuseppe Vergaro, Liam A. McDonnell, Angela Pucci   +10 more
doaj   +1 more source

Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition [PDF]

, 2018
Each of the 30 human amyloid diseases is associated with the aggregation of a particular precursor protein into amyloid fibrils. In transthyretin amyloidosis (ATTR), mutant or wild-type forms of the serum carrier protein transthyretin (TTR), synthesized ...
Benson, Merrill D., Chung, Kevin, Cohn, Whitaker, Eisenberg, David S., Lee, Ji H., Saelices, Lorena, Whitelegge, Julian P.   +6 more
core   +1 more source

Quality of life in ATTR amyloidosis [PDF]

Orphanet Journal of Rare Diseases, 2015
Methods As part of a protocolised model of care involving comprehensive annual clinical evaluation (including DPD scintigraphy, echocardiography, ECG, neurological testing, cardiac magnetic resonance imaging (CMR), 6-minute walk test and blood tests), patients completed the KCCQ and SF-36 questionnaires.
Lane, Thirusha, Bangova, Alica, Fontana, Marianna, Hutt, David F, Strehina, Svetla G, Whelan, Carol J, Hawkins, Philip N, Gillmore, Julian D   +7 more
openaire   +1 more source

Characterization of heterozygous ATTR Tyr114Cys amyloidosis-specific induced pluripotent stem cells

Heliyon
Hereditary transthyretin (TTR) amyloidosis (ATTRv amyloidosis) is autosomal dominant and caused by mutation of TTR gene. Heterozygous ATTR Tyr114Cys (p.Tyr134Cys) amyloidosis is a lethal disease with a life expectancy of about 10 years after onset of the
Kenta Ouchi, Kaori Isono, Yuki Ohya, Nobuaki Shiraki, Masayoshi Tasaki, Yukihiro Inomata, Mitsuharu Ueda, Takumi Era, Shoen Kume, Yukio Ando, Hirofumi Jono   +10 more
doaj   +1 more source

PET-CMR in heart failure - synergistic or redundant imaging? [PDF]

, 2017
Imaging in heart failure (HF) provides data for diagnosis, prognosis and disease monitoring. Both MRI and nuclear imaging techniques have been successfully used for this purpose in HF.
Quail, MA, Sinusas, AJ
core   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

A rare variant in the TTR gene (p.E112K) is associated with systemic amyloidosis and a new symptom – skin hyperemia in response to ethanol intake: family segregation analysis, literature review, and a clinical case. Case report

Терапевтический архив, 2023
Transthyretin amyloidosis (ATTR-amyloidosis) is a systemic disorder associated with extracellular deposition in the tissues and organs of amyloid fibrils, transthyretin-containing insoluble protein-polysaccharide complexes.
Olga S. Chumakova, Svetlana N. Nasonova, Yulia V. Frolova, Elena A. Stepanova, Elena A. Mershina, Valentin E. Sinitsyn, Dmitry A. Zateyshchikov, Igor V. Zhirov   +7 more
doaj   +1 more source

Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background The relationship between structural pathology and electrophysiological substrate in cardiac amyloidosis is unclear. Differences between light‐chain (AL) and transthyretin (ATTR) cardiac amyloidosis may have prognostic implications. Methods and
Michele Orini, Adam J. Graham, Ana Martinez‐Naharro, Christopher M. Andrews, Antonio de Marvao, Ben Statton, Stuart A. Cook, Declan P. O'Regan, Philip N. Hawkins, Yoram Rudy, Marianna Fontana, Pier D. Lambiase   +11 more
doaj   +1 more source